Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc.verified

RXDX

Price:

$199.92

Market Cap:

$9.56B

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated disea...[Read more]

Industry

Biotechnology

IPO Date

2021-03-12

Stock Exchange

NASDAQ

Ticker

RXDX

The Enterprise Value as of December 2024 (TTM) for Prometheus Biosciences, Inc. (RXDX) is 9.30B

According to Prometheus Biosciences, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 9.30B. This represents a change of 188.66% compared to the average of 3.22B of the last 4 quarters.

Prometheus Biosciences, Inc. (RXDX) Historical Enterprise Value (quarterly & annually)

How has RXDX Enterprise Value performed in the past?

The mean historical Enterprise Value of Prometheus Biosciences, Inc. over the last ten years is 1.27B. The current 9.30B Enterprise Value has changed 73.04% with respect to the historical average. Over the past ten years (40 quarters), RXDX's Enterprise Value was at its highest in in the March 2023 quarter at 5.01B. The Enterprise Value was at its lowest in in the March 2021 quarter at -151597832.08.

Quarterly (TTM)
Annual

Average

1.27B

Median

828.42M

Minimum

477.39M

Maximum

4.21B

Prometheus Biosciences, Inc. (RXDX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Prometheus Biosciences, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 328.34%

Maximum Annual Enterprise Value = 4.21B

Minimum Annual Increase = -36.25%

Minimum Annual Enterprise Value = 477.39M

Quarterly (TTM)
Annual
YearEnterprise ValueChange
20224.21B328.34%
2021981.70M18.50%
2020828.42M22.19%
2019678.00M-36.25%
20161.06B60.45%
2015662.88M38.85%

Prometheus Biosciences, Inc. (RXDX) Average Enterprise Value

How has RXDX Enterprise Value performed in the past?

The current Enterprise Value of Prometheus Biosciences, Inc. (RXDX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

3-year avg

2.01B

5-year avg

1.55B

10-year avg

1.27B

Prometheus Biosciences, Inc. (RXDX) Enterprise Value vs. Peers

How is RXDX’s Enterprise Value compared to its peers?

Prometheus Biosciences, Inc.’s Enterprise Value is greater than Apellis Pharmaceuticals, Inc. (4.20B), greater than Akero Therapeutics, Inc. (1.70B), greater than Immunovant, Inc. (3.31B), greater than Madrigal Pharmaceuticals, Inc. (6.67B), greater than Roivant Sciences Ltd. (6.80B), greater than Krystal Biotech, Inc. (4.25B), greater than 89bio, Inc. (885.64M), greater than Pliant Therapeutics, Inc. (792.38M), greater than Arcellx, Inc. (4.06B), greater than Stoke Therapeutics, Inc. (467.23M), greater than Viking Therapeutics, Inc. (4.67B), greater than Intercept Pharmaceuticals, Inc. (915.81M), greater than Terns Pharmaceuticals, Inc. (234.86M), greater than Reata Pharmaceuticals, Inc. (6.64B), greater than IVERIC bio, Inc. (5.13B), greater than Blueprint Medicines Corporation (6.12B), greater than Amylyx Pharmaceuticals, Inc. (209.72M), less than Karuna Therapeutics, Inc. (12.43B), greater than Day One Biopharmaceuticals, Inc. (859.59M),

Build a custom stock screener for Prometheus Biosciences, Inc. (RXDX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Prometheus Biosciences, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Prometheus Biosciences, Inc. (RXDX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Prometheus Biosciences, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the Enterprise Value?

How can you use the Enterprise Value?

What is Prometheus Biosciences, Inc.'s Enterprise Value?

What is the highest Enterprise Value for Prometheus Biosciences, Inc. (RXDX)?

What is the 3-year average Enterprise Value for Prometheus Biosciences, Inc. (RXDX)?

What is the 5-year average Enterprise Value for Prometheus Biosciences, Inc. (RXDX)?

How does the current Enterprise Value for Prometheus Biosciences, Inc. (RXDX) compare to its historical average?